Hofer, Silvia; Elandt, Katarzyna; Greil, Richard; Hottinger, Andreas F; Huber, Urs; Lemke, Dieter; Marosi, Christine; Ochsenbein, Adrian; Pichler, Josef; Roelcke, Ulrich; Weder, Patrik; Zander, Thilo; Wick, Wolfgang; Weller, Michael (2011). Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials. Acta oncologica, 50(5), pp. 630-5. Stockholm: Acta Oncologica 10.3109/0284186X.2011.572913
Full text not available from this repository.Patients with recurrent high-grade glioma (HGG) have a poor prognosis and there is no defined standard of care. High levels of vascular endothelial growth factor (VEGF) expressed in HGG make the anti-VEGF monoclonal antibody bevacizumab (BEV) of particular interest.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology |
UniBE Contributor: |
Ochsenbein, Adrian |
ISSN: |
0284-186X |
Publisher: |
Acta Oncologica |
Language: |
English |
Submitter: |
Factscience Import |
Date Deposited: |
04 Oct 2013 14:20 |
Last Modified: |
05 Dec 2022 14:05 |
Publisher DOI: |
10.3109/0284186X.2011.572913 |
PubMed ID: |
21495907 |
Web of Science ID: |
000290631600003 |
URI: |
https://boris.unibe.ch/id/eprint/6460 (FactScience: 211426) |
Actions (login required)
 |
Edit item |